Eric Sagonowsky
FiercePharma
Washington, DC, United States
Contact Eric
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Eric:
GSK, after consumer spinoff, touts momentum for core products Cabenuva and Shingrix
With GSK’s consumer healthcare spinoff now in the rearview mirror, | With GSK’s consumer healthcare spinoff now in the rearview mirror, the company is operating as the lean, innovative medicines-focused drugmaker CEO Emma Walmsley envisioned years ago. And 2022’s financial performance shows the company’s promise. → Read More
Seagen's targeted cancer med Tukysa picks up accelerated FDA nod in colorectal cancer
After welcoming a new CEO and entertaining a potential buyout last year, West Coast cancer specialist Seagen is again adding to its trophy case of regulatory wins. → Read More
JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amyrt buyout
During a day of travel for many in biopharma ahead of this year's annual J.P. Morgan Healthcare Conference, Italy’s Chiesi Farmaceutici kicked off the week with a buyout. | During a day of travel for many in biopharma ahead of the J.P. Morgan Healthcare Conference, Italy’s Chiesi Farmaceutici kicked off the week with a buyout. → Read More
After large asset swap, Sanofi and Boehringer expect answers in Zantac dispute this year
Like several other large drugmakers, Sanofi has been busy working through a web of litigation tied to the once-popular heartburn drug Zantac. | Like several other large drugmakers, Sanofi has been busy working through a web of litigation tied to the once-popular heartburn drug Zantac. But questions in a debate against Boehringer Ingelheim remain unanswered. → Read More
Horizon CEO Walbert in line for major payday after Amgen sale
Horizon Therapeutics CEO Timothy Walbert has made routine appearances in rankings of the biopharma ind | Horizon Therapeutics CEO Tim Walbert has made routine appearances in rankings of the biopharma industry's best-paid executives, and he's set to collect once again with his company's sale to Amgen. → Read More
Catalent opens cell therapy production site at Belgian 'center of excellence'
Catalent has spent several years—and hundreds of millions of dollars—setting up a cell therapy production campus in Belgium. | Catalent has spent several years—and hundreds of millions of dollars—setting up a world-class cell therapy production campus in Belgium. Thursday, it opened the newest site there. → Read More
In Jazz case, FTC urges court to delist patent on blockbuster Xyrem
The FTC says Jazz improperly listed a patent in the FDA's Orange Book, blocking a potential rival's launch. → Read More
Pfizer, riding high on COVID windfall, strikes $5.4B buyout of Global Blood Therapeutics
Riding high on its COVID-19 windfall, Pfizer has been busy scouring the biopharma landscape for new assets to bring into the fold. | Riding high on its COVID-19 windfall, Pfizer has been busy scouring the biopharma landscape for new assets to bring into the fold. Now, the drugmaker has inked a buyout of Global Blood Therapeutics and its marketed sickle cell disease drug, Oxbryta. → Read More
Negotiations? AbbVie CEO says current Senate proposal brings 'price controls' instead
While lawmakers are busy working on the reconciliation bill that may take a serious stab at drug prices, pharmaceutical companies are on defense. → Read More
'Leaner and simpler': Novartis details plans to cut 8,000 jobs worldwide
For months, Novartis has hinted at layoffs coming for some of its global staff | For months, Novartis has hinted at layoffs coming for some of its global staff. Now, the news has come down from HQ. → Read More
Bluebird scores 2nd straight win at high-stakes FDA gene therapy meeting
Bluebird has impressed an FDA panel and come away with a pair of expert endorsements for its lead drugs for sickle cell and cerebral adrenoleukodystrophy. → Read More
Days after US downsizing plan, Amarin scores a Vazkepa win in UK
After stumbling in the all-important U.S. market, struggling Amarin has scored a needed win overseas. | After stumbling in the all-important U.S. market, struggling Amarin has scored a needed win overseas. In the U.K., the National Institute for Health and Care Excellence has endorsed Vazkepa for about 425,000 patients with elevated levels of triglycerides, a type of blood fat. → Read More
Moderna's new CFO out the door one month into his gig after former employer discloses probe
Moderna is bringing back its former finance chief David Meline only a month after unveiling a CFO switch. → Read More
Teva faces $100M lawsuit from Israel over unpaid Copaxone royalties: report
Teva's Copaxone is at the center of a $100M lawsuit from the state of Israel over alleged unpaid royalties. → Read More
GSK, Vir's COVID antibody put on ice as BA.2 subvariant takes hold
Throughout the COVID-19 pandemic, emerging variants have prompted regulators to force antibody products off the market if testing showed that they were no longer effective against the disease. → Read More
On a roll, Sanofi raises Dupixent's peak sales target to €13B-plus
Over the years, as Sanofi and Regeneron's Dupixent racked up new indications and approached the French pharma giant's 10 billion euro peak sales goal, analysts had started to wonder whether the dru → Read More
Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters
When Gilead Sciences picked up Immunomedics and the breast cancer drug T | When Gilead Sciences picked up Immunomedics and the breast cancer drug Trodelvy for $21 billion a couple years back, the company billed the buyout as a major expansion into oncology. Now, the California-based drugmaker is laying off more than 100 staffers based out of the former Immunomedics headquarters as it gears up… → Read More
The top 10 drugs losing US exclusivity in 2022
With AbbVie’s megablockbuster Humira set to face an onslaught of biosimilars next year, industry watchers have long circled 2023 as the year of the major pharma patent cliff. But this year’s slate of top losses of exclusivity covers sizable brands worth more than $17 billion in annual sales. → Read More
Johnson & Johnson, Moderna set to face shareholder votes on vaccine pricing strategy, manufacturing tech sharing
Throughout the global push to produce COVID-19 vaccines, pharma companies have frequently come under fire for unequal access to their shots. Oxfam, in a bid to force better access, has scored a pair of wins in its effort to exact pricing and intellectual property information from Johnson & Johnson and Moderna, respectively. → Read More
Karyopharm ready to take new Xpovio indication to the FDA but analysts hold out for details
After a tough path to the market, Karyopharm scored a series of FDA approvals for Xpovio in recent years for multiple myeloma and diffuse large B-cell lymphoma. Now, it's looking to take the momentum forward into another cancer indication and move the drug to an earlier line of treatment, which would open up a bigger market. → Read More